Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Albert Losken

Plastic Surgery Atlanta, GA Medical Doctor

NPI 1932166766 CMS profile 223215

550 Peachtree St, 8Th Floor Ste 4300, Atlanta, GA 30308

Open in the dashboard

General payments

$435,810

106 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$24,224 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Albert Losken of Atlanta, GA is reported in the CMS Open Payments database as having received $435,810 across 106 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $24,224 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $119,912 16
2024 General $50,030 14
2023 General $33,081 17
2022 General $152,691 15
2021 General $37,458 18
2020 General $2,658 4
2019 General $39,980 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Albert Losken
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Albert Losken were reported at $119,912. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Albert Losken Plastic Surgery median Middle half National median
2019 $39,980 $371 $122–$1,483 $163
2020 $2,658 $158 $52–$438 $114
2021 $37,458 $249 $87–$752 $132
2022 $152,691 $274 $102–$793 $149
2023 $33,081 $299 $113–$891 $160
2024 $50,030 $361 $124–$1,062 $164
2025 $119,912 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. RTI Surgical, Inc $164,230 33 payments
  2. Surgical Innovation Associates, Inc. $131,857 1 payment
  3. Bimini Technologies LLC $92,400 1 payment
  4. RTI Surgical, Inc. $41,723 15 payments
  5. AbbVie, Inc. $738 6 payments
  6. Mentor Worldwide LLC $735 9 payments
  7. TELA Bio, Inc. $700 6 payments
  8. Sientra, Inc. $578 4 payments
  9. Kerecis Limited $401 2 payments
  10. Dilon Technologies, Inc. $306 2 payments
  11. Other $2,142 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $152,015 17 payments
  2. Consulting Fee $142,862 17 payments
  3. Acquisitions $131,857 1 payment
  4. Food and Beverage $6,845 66 payments
  5. Travel and Lodging $2,231 5 payments
Products named General payments · program years 2019–2025
  1. CORTIVA ALLOGRAFT DERMIS General and Plastic Surgery $164,046 26 payments
  2. DuraSorb Monofilament Mesh $131,857 1 payment
  3. CORTIVA TAILORED ALLOGRAFT DERMIS $36,910 12 payments
  4. CORTIVA ALLOGRAFT DERMIS General and Plastic Surgery $2,500 1 payment
  5. ALLOGRAFT $2,414 8 payments
  6. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $578 4 payments
  7. OviTex 2S $524 4 payments
  8. MENTOR MemoryGel Resterilizable Gel Sizer $511 6 payments
  9. ALLODERM $466 4 payments
  10. Kerecis Omega3 SurgiClose $401 2 payments
  11. Other $4,590 42 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

165

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$641

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

7.3%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 78 $446
Oxycodone Hcl Generic 59 $125
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 12 $40
Ibuprofen Generic 16 $30

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$60,022

Medicare's payments for the services billed

Medicare patients

120

Average age 70

Services billed

260

104 women, 16 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 70%
High blood pressure 67%
Arthritis 45%
Diabetes 24%
Chronic kidney disease 23%
Osteoporosis 22%
Depression 20%
Ischemic heart disease 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

106 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record